Drug Guide

Generic Name

Perfluorohexyloctane

Brand Names Miebo

Classification

Therapeutic: Ophthalmic lubricant

Pharmacological: Perfluorocarbon liquid

FDA Approved Indications

  • Treatment of dry eye disease, especially evaporative dry eye due to meibomian gland dysfunction

Mechanism of Action

Forms a temporary, lubricating barrier on the surface of the eye to reduce tear evaporation and improve ocular surface hydration.

Dosage and Administration

Adult: Instill 1-2 drops into the affected eye(s) once or twice daily, as needed.

Pediatric: Data limited; use only if prescribed by ophthalmologist.

Geriatric: Adjust dosage based on patient's clinical response and tolerability.

Renal Impairment: No specific adjustments needed; consider ocular route.

Hepatic Impairment: Data limited; use with caution.

Pharmacokinetics

Absorption: Minimal systemic absorption due to topical ocular application.

Distribution: Localized on ocular surface.

Metabolism: Not metabolized systemically.

Excretion: Excreted via tear film; minimal systemic excretion.

Half Life: N/A; localized effect duration varies, but typically few hours.

Contraindications

  • Known hypersensitivity to perfluorocarbons or any component of the formulation.

Precautions

  • Use with caution in patients with ocular infections or injuries.
  • Monitor for adverse reactions such as visual disturbances or irritation.

Adverse Reactions - Common

  • Transient blurred vision (Common)
  • Ocular irritation or redness (Common)

Adverse Reactions - Serious

  • Severe allergic reaction, including swelling or difficulty breathing (Rare)
  • Significant ocular pain or signs of infection (Rare)

Drug-Drug Interactions

  • Limited data; generally minimal due to topical application.

Drug-Food Interactions

  • No known interactions.

Drug-Herb Interactions

  • None established.

Nursing Implications

Assessment: Assess ocular surface condition, visual acuity, and patient’s response.

Diagnoses:

  • Risk for impaired vision
  • Ineffective peripheral tissue perfusion related to ocular surface irritation.

Implementation: Administer as prescribed, ensuring proper instillation technique.

Evaluation: Monitor symptom relief, adverse reactions, and ocular health status.

Patient/Family Teaching

  • Instruct to use the drops as directed.
  • Warn about possible visual disturbances following instillation.
  • Advise to seek medical attention if adverse reactions occur or symptoms worsen.

Special Considerations

Black Box Warnings:

  • None

Genetic Factors: None known.

Lab Test Interference: None.

Overdose Management

Signs/Symptoms: No systemic overdose expected; ocular overdose may cause increased irritation or blurred vision.

Treatment: Rinse eye with sterile saline or water; provide symptomatic care; seek ophthalmic evaluation if necessary.

Storage and Handling

Storage: Store at room temperature, away from direct sunlight and moisture.

Stability: Stable until the expiration date on the package.

This guide is for educational purposes only and is not intended for clinical use.